ArticleThe Journal of infectious diseases2008
Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.
Article in The Journal of infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Genetic polymorphisms -137 (rs187238) and -607 (rs1946518) in the interleukin-18 promoter may not be associated with development of hepatocellular carcinoma.Scientific reports · 2016Pooled it
- Microbiota and mycobiota in chronic inflammatory demyelinating polyneuropathy: clinical and pathophysiological correlations.Frontiers in molecular neuroscience · 2026Article
- Genetic and metabolic inflammation signatures in chronic inflammatory demyelinating polyneuropathy: the role ofFrontiers in molecular neuroscience · 2025Article
- Associations of Single Nucleotide Polymorphisms in IL-18 Gene withJournal of inflammation research · 2021Article
- Impacts of Interleukin-18 Polymorphisms on the Incidence of Delayed-Onset Cytomegalovirus Infection in a Cohort of Kidney Transplant Recipients.Open forum infectious diseases · 2019Article
- Associations of human leukocyte antigen and interleukin-18 gene polymorphisms with viral load in patients with hepatitis B infection.Medicine · 2018Article
- Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.Journal of clinical and experimental hepatology · 2018Article
- Direct-Acting Antiviral Agents for HCV Infection.Journal of clinical and experimental hepatology · 2018Article
- Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- IL18 Gene Variants Influence the Susceptibility to Chagas Disease.PLoS neglected tropical diseases · 2016Article
- Progress in the development of vaccines for hepatitis C virus infection.World journal of gastroenterology · 2015Review
- Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.Hepatology (Baltimore, Md.) · 2015Article
- Natural evolution of hepatitis C virus infection in hemodialysis Tunisian patients and CTLA-4 SNP's.World journal of gastroenterology · 2015Article
- Article
- Hepatitis C virus (HCV) interaction with astrocytes: nonproductive infection and induction of IL-18.Journal of neurovirology · 2014Article
- Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies?Cancer letters · 2014Review
- Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.Hepatic medicine : evidence and research · 2014Review
- Immunity and hepatitis C: a review.Current HIV/AIDS reports · 2013Review
- High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection.The Journal of infectious diseases · 2011Article
- Functional promoter haplotypes of interleukin-18 condition susceptibility to severe malarial anemia and childhood mortality.Infection and immunity · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
The immune response is critical in determining the outcome of hepatitis C virus (HCV) infection. Interleukin (IL)-18 is a pivotal mediator of the Th1/Th2-driven immune response. Two IL-18 promoter polymorphisms (-607C/A and -137G/C) and their haplotypes were known to affect IL-18 expression. We examined the role played by these polymorphisms in determining HCV clearance or persistence. Genotyping was performed among African American injection drug users with HCV clearance (n = 91) or HCV persistence (n = 182) and among European Americans with hemophilia who were mainly infected through plasma transfusion. Among injection drug users, IL18 -607A (odds ratio [OR], 3.68 [95% confidence interval {CI},1.85-7.34]) and IL18 -137C (OR, 2.33 [95% CI, 1.24-4.36]) were significantly associated with HCV clearance. A haplotype carrying -607A and -137C (OR, 4.53 [95% CI, 1.77-11.6]) was also strongly associated with viral clearance. No association was found among those with hemophilia. These results suggest that IL18 promoter polymorphism may affect the outcome of HCV infection in certain groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.